Carriers Comprising Colloidal Metal Praticles for Translocation into Cerberal Neurons
The present inventors intravenously administered laboratory animals with molecules in which peptides and colloidal metal particles had been bound, to discover that the molecules translocated to the brain, specifically into cerebral neurons. Since activity to translocate into cerebral neurons could not be observed when the metal colloids were not bound, this activity was suggested to be a property of the colloidal metal particles. Desired compounds can be translocated into cerebral neurons by binding them to the colloidal metal particles. Furthermore, by using as carriers conjugate molecules in which peptides having brain-localizing activity are bound to the colloidal metal particles of the present invention, desired compounds can be delivered into cerebral neurons by intravenous administration.
1 . A colloidal metal particle having activity to translocate into a cerebral neuron.
2 . A carrier molecule for translocation into a cerebral neuron, wherein the molecule comprises a colloidal metal particle.
3 . The carrier molecule of claim 2 having the activity to translocate from cerebral parenchyma into a cerebral neuron.
4 . The carrier molecule of claim 2 or 3 , wherein an avidin molecule is bound to the surface of the colloidal metal particle.
5 . The carrier molecule of any one of claims 2 to 4 , wherein the metal is gold.
6 . A colloidal solution for translocation into a cerebral neuron, in which the carrier molecule of any one of claims 2 to 5 is present in a dispersed state in solution.
7 . A therapeutic agent for a brain disease, wherein the agent comprises as an active ingredient a carrier molecule of any one of claims 2 to 5 that supports a therapeutic compound for a brain disease.
8 . A therapeutic agent for a brain disease, wherein the agent comprises as an active ingredient the colloidal solution of claim 6 , in which a carrier molecule supporting a therapeutic compound for a brain disease is present.
9 . A method for producing a pharmaceutical agent that translocates into a cerebral neuron, wherein the method comprises the step of contacting a therapeutic compound for a brain disease with a carrier molecule of any one of claims 2 to 5 .